EMA approves Roche's Gazyvaro shorter 90─minute infusion time for people with previously treated or untreated follicular lymphoma

Roche announced European Medicines Agency (EMA) approval of a new, shorter 90─minute Gazyvaro (obinutuzumab) infusion time, administered in combination with chemotherapy in patients with previously treated or untreated advanced follicular lymphoma (FL).